Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HG102 vs Botox for Glabellar Lines
NCT05801146Phase 3Recruiting
- Sponsor
- Hugel
- Start
- Jan 2024
- Primary completion
- Mar 2025
- Modality
- Therapeutic Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of letibotulinumtoxinA in glabellar lines (2 arms), sponsored by Hugel. Primary endpoint: Responder rate of improvement in glabellar lines with Physician's rating line severity at 4 weeks. Started Jan 2024; status: recruiting.
02
Drugs
letibotulinumtoxinA
03
Conditions
glabellar lines
Beyond the preview
Go deeper on NCT05801146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05801146.